北美液体活检市场预测至 2027 年 - COVID-19 影响以及产品和服务区域分析（设备、试剂和试剂盒以及服务）；样品（血液样品、尿液样品和其他样品）；循环生物标志物（循环肿瘤细胞（CTC）、外泌体和游离核酸）；应用（无创产前检测（NIPT）、肿瘤学、移植诊断和其他应用）；最终用户（学术和研究机构、医院、参考实验室和其他最终用户）；以及，国家
No. of Pages: 143 | Report Code: TIPRE00013010 | Category: Life Sciences
No. of Pages: 143 | Report Code: TIPRE00013010 | Category: Life Sciences
液体活检是一项革命性技术，它开辟了多种视角。该技术包括分离和检测循环肿瘤细胞、循环肿瘤DNA和外泌体，提供癌症患者的基因组信息。液体活检用于癌症诊断，以研究对特定治疗的反应或耐药性。
此外，在美国，由于感染患者数量不断增加，医疗保健专业人员和领先组织正在分散流程来自研究和的医疗保健资源发展到初级保健，这减缓了创新的进程。此外，大流行的蔓延也阻碍了美国的临床试验、药物开发和诊断行业。例如，总部位于加利福尼亚州的 Lucence Diagnostics Pte Ltd. 开发液体活检并在该行业拥有知名企业，但现在已转而生产 COVID-19 试剂盒。
北美液体活检市场预计将从 2027 年的 15.2258 亿美元增至 2027 年的 35.3144 亿美元。 2018 年。预计 2019 年至 2027 年市场复合年增长率为 10.1%。推动市场增长的因素包括癌症患病率的增加。然而，液体活检的低敏感性可能会对市场增长产生负面影响。
产品与就服务而言，试剂和试剂盒细分市场在 2018 年北美液体活检市场中占据最大市场份额。就样本而言，到 2027 年，基于血液的细分市场将在液体活检市场中占据最大市场份额。通过流通生物标志物， 2019年，循环肿瘤细胞（CTC）细分市场在北美液体活检市场中占据最大市场份额。到2027年，肿瘤学细分市场按应用占据最大市场份额。此外，就最终用户而言，到 2027 年，参考实验室细分市场将占据液体活检市场的最大市场份额。
报告中包含的液体活检市场的一些主要主要和次要来源包括美国癌症协会 (ACR)、疾病控制和预防中心 ( CDC）、食品和药物管理局（FDA）、国际糖尿病联合会（IDF）等。
< p>
< strong>按地理位置
• 北美洲
< strong>公司简介
Strategic insights for North America Liquid Biopsy involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2018 | US$ 1,522.58 Million |
| Market Size by 2027 | US$ 3,531.44 Million |
| Global CAGR (2019 - 2027) | 10.1% |
| Historical Data | 2016-2017 |
| Forecast period | 2019-2027 |
| Segments Covered |
By 产品与服务
|
| Regions and Countries Covered | 北美
|
| Market leaders and key company profiles |
The regional scope of North America Liquid Biopsy refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The North America Liquid Biopsy Market is valued at US$ 1,522.58 Million in 2018, it is projected to reach US$ 3,531.44 Million by 2027.
As per our report North America Liquid Biopsy Market, the market size is valued at US$ 1,522.58 Million in 2018, projecting it to reach US$ 3,531.44 Million by 2027. This translates to a CAGR of approximately 10.1% during the forecast period.
The North America Liquid Biopsy Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Liquid Biopsy Market report:
The North America Liquid Biopsy Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Liquid Biopsy Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Liquid Biopsy Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Liquid Biopsy Market
